The Burden of Pancreatic Cancer From Asia in 2022 and Predictions to 2050 According to GLOBOCAN Estimates

ABSTRACT Background Pancreatic cancer is a malignant tumor with high incidence and mortality, which imposes a significant burden on individuals, families and the society. This study evaluates the regional burden and epidemiological trends of pancreatic cancer from Asia in 2022, and predicts the incidence and mortality trends in the next 30 years. Methods A series of data on the number of new pancreatic cancer cases and death population estimated in 2022 are retrieved from GLOBOCAN 2022 database, using the world standard method of calculating age‐standardized rates. This study analyzes the burden and epidemiological trends of pancreatic cancer in 48 countries in Asia from four aspects. It predicts the incidence and mortality for the next 30 years. Results The incidence of pancreatic cancer in each country is roughly proportional to mortality and Human Development Index. Both in terms of incidence and mortality, Japan bears the highest burden, whereas Pakistan has the lowest burden. In the whole age group, the incidence of pancreatic cancer is mainly concentrated in males and middle‐aged or elderly people, but in Japan and South Korea, due to other risk factors (diet, obesity, occupational factors, etc.), the incidence of pancreatic cancer is mainly concentrated in women. Up to 2050, 487,000 new cases of pancreatic cancer and 459,000 new deaths from pancreatic cancer are expected to occur. Conclusion The observed trends and predictions indicate that the burden of pancreatic cancer will continue to increase, especially in economically developed regions. It is recommended that in high‐risk countries, tobacco control, alcohol restriction, promotion of physical examinations and physical exercise be initiated as early as possible, and a regional monitoring network should be established, with a focus on screening high‐risk groups (such as those with long‐term obesity and smoking) to stabilize the incidence and mortality indicators. Trial Registration This is a cross‐sectional study derived from the GLOBOCAN database. Therefore, clinical trial registration was not conducted